JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deonarain, R.
Right arrow Articles by Porter, A. C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deonarain, R.
Right arrow Articles by Porter, A. C. G.

Journal of Virology, April 2000, p. 3404-3409, Vol. 74, No. 7
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Impaired Antiviral Response and Alpha/Beta Interferon Induction in Mice Lacking Beta Interferon

Raj Deonarain,1 Antonio Alcamí,2 Maria Alexiou,1 Margaret J. Dallman,3 Dirk R. Gewert,4,* and Andrew C. G. Porter1,*

MRC Clinical Science Centre, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN,1 Division of Virology, Department of Pathology, Cambridge University, Cambridge CB2 1QP,2 Department of Biology, Imperial College of Science Technology and Medicine, South Kensington, London SW7 2AZ,3 and QT Genetics Ltd., Cambridge CB4 3GA,4 United Kingdom

Received 8 September 1999/Accepted 30 December 1999


    ABSTRACT
Top
Abstract
Text
References

We have generated mice lacking the gene for beta interferon and report that they are highly susceptible to vaccinia virus infection. Furthermore, in cultured embryo fibroblasts, viral induction of alpha interferon and of 2-5A synthetase genes is impaired. We also show that beta interferon does not prime its own expression.


    TEXT
Top
Abstract
Text
References

Interferons (IFNs) consist of a family of evolutionarily conserved proteins encoded by closely related and linked genes. Alpha/beta IFNs (IFN-alpha /beta ), represented by several IFN-alpha subtypes, IFN-beta , and IFN-omega , bind to a common cell surface receptor, resulting in the activation of the Jak-STAT signal transduction system (7, 8) and leading to the transcriptional activation of IFN-stimulated genes. The products of these genes must account not only for the versatile antiviral effects of IFNs but also for their immunomodulatory and antiproliferative effects. The roles of some of these proteins, including 2-5A synthetase, in establishing an antiviral state have been described (25, 34, 38).

IFN plays an important role in the protection against infection by a large number of viruses, including vaccinia virus and other poxviruses (39). This is emphasized by the expression of a number of different anti-interferon strategies by viruses, including soluble IFN receptors and intracellular proteins that block the activities of key interferon-inducible genes (40).

IFN-alpha /beta are expressed by cells within hours of infection by virus and can act in an autocrine or paracrine manner to limit the development and spread of viral infection. This primary role for IFN-alpha /beta in vivo is confirmed in studies with mice lacking one of the two chains of the functional IFN-alpha /beta receptor: these animals display an extreme sensitivity to infection by viral pathogens. However, these studies did not differentiate between the roles of IFN-alpha and IFN-beta in the antiviral response (44).

Despite these advances in our knowledge, our understanding of the IFN-alpha /beta system is still far from complete. First, it is not known why there are so many IFN-alpha /beta genes. In mice, there are at least 12 IFN-alpha genes and a single IFN-beta gene clustered on chromosome 4 (18), and the protein product of any one of these appears to be sufficient to generate an antiviral state in responsive cells (19). Second, it is not known how the role of IFN-beta differs from that of the various IFN-alpha subtypes. Whereas the murine IFN-alpha genes have ~90% homology, murine IFN-beta appears to be rather more divergent, with only ~55% homology to a murine IFN-alpha consensus sequence. Third, the exact nature of the inducers for IFN-alpha /beta is uncertain. It is known that double-stranded RNA, produced during a variety of viral infections, can induce transcription of IFN-alpha /beta genes, but nonviral inducers have also been described (4, 36, 41). Induction of the IFNbeta gene has been extensively studied in cell culture, leading to a detailed knowledge of cis-acting sequences and binding factors required for transcriptional induction (16); a similar but less complete analysis of IFN-alpha induction has been carried out (27). Nonetheless, the precise nature of the inducer for particular viral infections is unknown and details of the pathway(s) leading to transcriptional activation are still sketchy. Finally, the importance of the kinetics of IFN-alpha /beta induction and the identity of the cellular source of IFN-alpha /beta induction during an in vivo infection are unclear. Thus, although it is known that IFN-alpha /beta can be induced in a wide variety of cell types, it is unclear whether induction in the initially infected cell type is sufficient for a proper defense or whether paracrine IFN activity on other cell types is important.

We reasoned that a mouse in which the endogenous IFN-beta genes have been deleted would be useful in determining whether IFN-alpha can compensate for the loss of IFN-beta . Furthermore, by replacing the IFN-beta gene with a reporter, the same mice should yield information concerning the source, control, and timing of IFN-beta gene expression. In a similar approach, another group (13) provided evidence for a role for IFN-beta in IFN-alpha induction but did not establish whether the effect was of physiological significance.

Generation and preliminary analysis of IFN-beta -/- mice. Targeting constructs were designed to delete the IFN-beta gene and replace it with a reporter gene for green fluorescent protein (GFP) (30) or hCD2 (26) (Fig. 1a and b). The virus inducibility of the reporter genes was confirmed in human 293 cells stably transfected with these constructs (Fig. 1c and d). HM-1 embryonic stem cells (22) transfected with the constructs were screened by Southern blotting (46) and targeted clones were detected at a frequency of about 1 per 40 G418-resistant clones (Fig. 1e and f). Several targeted clones were separately injected into C57BL/6 blastocysts, and resulting chimeric mice were tested for germ line transmission of the transgene in crosses with C57BL/6 mice. One chimera carrying the Mubeta GFP/neo transgene showed efficient germ line transmission, and F1 heterozygotes from this chimera were identified by PCR analysis of tail biopsies. These IFN-beta +/- offspring were crossed to generate IFN-beta +/+, IFN-beta +/-, and IFN-beta -/- F2 pups as well as mouse embryo fibroblasts (MEFs) (17). Genotypes of pups and MEFs were determined by PCR (Table 1) as illustrated for MEFs in Fig. 1g. In addition, Southern analyses of DNA from the MEFs showed the expected pattern of bands diagnostic for normal and targeted IFNbeta genes (Fig. 1h). The MEFs were also tested by reverse transcription-PCR (RT-PCR) for IFN-beta and GFP mRNA induction following viral infection. As expected, IFN-beta expression was not detected in IFN-beta -/- MEFs, while a clear virus-inducible signal was detected in both IFN-beta +/- and IFN-beta +/+ MEFs. Similarly, GFP expression was detectable following virus induction of both IFN-beta +/- and IFN-beta -/- MEFs but was not detected at all in IFN-beta +/+ MEFs (Fig. 2). The GFP reporter was therefore under the control of the virus inducible elements of the IFNbeta gene locus. A further observation from the induction of these MEF cells is that the inducibility of the GFP reporter is apparently the same in both IFN-beta +/- and IFN-beta -/- cells. This suggests that IFN-beta does not have any marked effect on the inducibility of the IFNbeta promoter following virus induction. This contrasts with the transcription-enhancing activity reported by others (12, 20) for IFN-alpha /beta on the IFNbeta regulatory elements.


View larger version (50K):
[in this window]
[in a new window]
 
FIG. 1.   Design and use of IFNbeta targeting constructs and genotyping of MEFs from an ES clone targeted with pMubeta GFP/neo. Details of plasmid construction and conditions for cell growth and transfection are described elsewhere (9). (a) The targeting construct pMubeta GFP/neo (NotI linearized; top), the IFNbeta locus (center), and the product of homologous recombination between them (bottom) are represented as follows: IFNbeta gene (black box), IFNbeta promoter region (ellipse), other DNA from the IFNbeta locus (thick black lines), GFP gene (white box; from pRSGFP [Clontech]), neo cassette (stippled box), loxP site (black triangle), and pBSKSII+ DNA (thin line). Key sites for BamHI (B) and resulting fragments detectable by probe a (black bar) are shown. (b) As for panel a except for targeting construct pMubeta CD2/neo; white box represents human CD2 gene. (c) Flow cytometric analysis of GFP expression in a G418-resistant 293 clone stably transfected with pMubeta GFP/neo, either without induction or 48 h after induction by Sendai virus infection. (d) Flow cytometric analysis of CD2 expression in a pool of 293 G418-resistant 293 clones stably transfected with pMubCD2/neo, either without induction or 48 h after induction by Sendai virus infection. Conditions for electroporation, infection, and flow cytometry in panels c and d have been previously described (9) and are available on request. (e) Screening by Southern analysis for ES cell clones targeted with pMubeta GFP/neo (18, 22). Analysis of BamHI-digested DNA from 10 G418-resistant clones probed with probe a. The 7.3-kb band representing the unmodified IFNbeta locus migrates differently in odd- and even-numbered lanes because one comb was used for odd lanes and another for even lanes. A targeted clone and its diagnostic band are indicated by vertical and horizontal arrows, respectively. (f) As for panel e but with targeting construct pMubeta CD2/neo. (g) Duplex PCR detection of IFNbeta and GFP genes in genomic DNA. ND, no template DNA. (h) Southern analysis of BamHI-digested MEF DNA probed with probe a or IFN-beta probe (a 460-bp BamHI-KpnI fragment of the IFNbeta gene). Size markers (M) are shown.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   PCR primers used in this study



View larger version (62K):
[in this window]
[in a new window]
 
FIG. 2.   RT-PCR assays for induction of IFN-alpha /beta , GFP, and 2-5A synthetase transcripts in IFN-beta +/+, IFN-beta +/-, and IFN-beta -/- MEFs. MEFs were infected with Sendai virus and harvested for RNA preparation either immediately (0 h) or 12 h later, as indicated. RNA (1 µg), prepared by lysis in guanidium isothiocyanate and density gradient centrifugation, was reverse transcribed (15-µl reaction mixtures containing avian myeloblastosis virus reverse transcriptase [Promega Biotech]) and, after the indicated dilutions, RT products (1 µl) were assayed by PCR for the following cDNAs: IFN-beta , GFP, 2-5A synthetase (2-5AS), all known IFN-alpha subtypes (Ualpha ), IFN-alpha -4 subtype (a4), all known IFN-alpha subtypes excluding IFN-alpha -4 (Nalpha 4) and, as a positive control, phosphoglycerate kinase (PGK). Conditions for PCRs are summarized in Table 1.

Increased susceptibility of IFN-beta -/- mice to viral infection. Because of the central role of IFN-alpha /beta in host response to viral infection, we investigated the effect of deletion of the IFNbeta gene on the progression of vaccinia virus infection. Following intranasal inoculation at three doses of virus, the course of infection was monitored by measuring weight loss and other indicators of infection, as previously described (2, 42). The results (Fig. 3) show a dramatically increased susceptibility to infection in IFN-beta -/- mice. At the lowest virus inoculum (103 PFU/animal), IFN-beta -deficient mice showed signs of illness and weight loss and a single animal died. All other animals showed no signs of disease, cleared the infection, and recovered the initial weight loss. At both 104 and 105 PFU/animal, all the IFN-beta -deficient mice succumbed to the infection after rapid weight loss and severe signs of illness. By contrast, the IFN-beta +/+ mice were more resistant to vaccinia virus, showing minor signs of illness and recovering from the infections, except for a single mortality at the intermediate virus dose. These data indicated that the IFN-beta -/- animals are highly susceptible to vaccinia virus infection and succumb to doses that are sublethal to animals able to express IFN-beta .


View larger version (30K):
[in this window]
[in a new window]
 
FIG. 3.   Vaccinia virus infection in IFN-beta +/+ and IFN-beta -/- mice. Groups of 7- to 9-week-old IFN-beta +/+ (open circles) or IFN-beta -/- mice (closed circles) were intranasally infected with 103, 104, or 105 PFU of vaccinia virus strain Western Reserve. Every day, mice were individually weighed and monitored for signs of illness, scored from zero to four (ruffled fur, arched backs, and reduced mobility), or death. The mean percentage weight loss of each group ± the standard error of the mean, relative to the weight immediately preceding the infection, and the mean value of signs of illness ± the standard error of the mean in groups of mice infected with the indicated doses of virus, are shown. The horizontal bars indicate those days in which differences were statistically significant when analyzed by Student's t test, and the P values are shown. The number of mice per group that either died or were sacrificed due to severe infection is shown in the insets.

The replication of vaccinia virus in different organs of mice was also investigated (Fig. 4). The lower doses of viral inoculum (103 PFU/animal) resulted in significantly higher titers of virus in the IFN-beta -/- mice than in IFN-beta +/+ animals, and this was particularly evident at the primary site of infection, the lungs. This difference in vaccinia virus replication was less evident at the higher inoculum tested (104 PFU/animal): at day 6 postinfection, vaccinia virus had replicated to similar levels in the absence or presence of IFN-beta . It is interesting, however, that the IFN-beta +/+ mice recovered from the infection at 104 PFU/animal whereas the IFN-beta -/- animals succumbed (Fig. 3). This suggests that IFN-beta may play a role in the recovery from an established vaccinia virus infection.


View larger version (26K):
[in this window]
[in a new window]
 
FIG. 4.   Vaccinia virus replication in IFN-beta +/+ and IFN-beta -/- mice (7 to 9 weeks old). Groups of IFN-beta +/+ (open circles) and IFN-beta -/- mice (closed circles) were infected intranasally with 103 or 104 PFU of vaccinia virus strain Western Reserve per animal as previously described (2, 42). On the indicated days postinfection, animals were sacrificed and infectious virus in Dounce-homogenized lungs, spleen, and brain was determined by plaque titration on BS-C-1 cell monolayers. The geometric mean (=) and titers in independent mice, expressed as PFU per organ, are presented. The dashed line indicates the detection limit of the assay.

Impaired IFN-alpha /beta response in IFN-beta -/- MEFs. As an indicator of the antiviral response, we used RT-PCR to measure induction of the gene encoding 2-5A synthetase in MEFs infected with virus. The results show a clear difference between IFN-beta -/- MEFs, in which 2-5A gene expression was weak, and IFN-beta +/- and IFN-beta +/+ MEFs, in which a robust induction was detected (Fig. 2). To explore the possible basis for the poor induction of 2-5A synthetase in IFN-beta -/- MEFs, we measured IFN-alpha induction in the same RNA samples, again by RT-PCR. A recent study (23) has indicated that the IFN-alpha -4 subtype is induced earlier than other IFN-alpha subtypes in response to viral induction. An RT-PCR was therefore designed to detect all known IFN-alpha transcripts (Ualpha ), another specific for the IFN-alpha -4 subtype (alpha 4), and a third to detect all IFN-alpha transcripts except IFN-alpha -4 (Non-alpha 4); all showed detectable induction in IFN-beta -/- MEFs, although the response was clearly impaired compared to that in IFN-beta +/+ and IFN-beta +/- MEFs (Fig. 2). The relatively low levels of the various IFN-alpha transcripts detected in RNA from IFN-beta -/- MEFs was not caused by a low quality or quantity of IFN-beta -/- RNA: control RT-PCR assays for transcripts encoding the housekeeping enzyme phosphoglycerate kinase (PGK) showed no difference between IFN-beta -/-, IFN-beta +/-, and IFN-beta -/- MEFs (Fig. 2). While the signal for Non-alpha 4 transcripts was particularly weak in IFN-beta -/- cells, it was clearly higher at 12 h than at 0 h after infection. It therefore appears that all IFN-alpha genes are at least partially dependent on IFN-beta for induction, although it remains possible that some species (e.g., Non-alpha 4) are more dependent than others (e.g., alpha 4).

The key finding in this report is that IFN-beta is required to mount an antiviral response following infection of mice with vaccinia virus. Mice deficient in the IFN-alpha /beta receptor have been reported to be more susceptible to viral infections, including vaccinia virus (43). However, because all IFN-alpha /beta subspecies are induced under broadly similar conditions, act through a single receptor system, and have each been shown to have antiviral activities, the in vivo antiviral effect could be mediated by any or all IFN-alpha /beta molecules, singly or in combination. The infection of IFN-beta -/- mice with vaccinia virus provided an opportunity to evaluate the specific in vivo role of IFN-beta in host defenses. The increased susceptibility of these animals to vaccinia virus was striking because the IFN-alpha s might be expected to compensate for loss of the single IFNbeta gene. That this is not the case indicates that IFN-beta performs some unique role that is essential for a full antiviral response.

At least two mechanisms can be envisaged to explain such a unique role for IFN-beta . In the first, IFNalpha and IFNbeta genes may be independently induced by viral infection, but IFN-beta may specifically induce one or more genes that are required for full antiviral activity. Consistent with this possibility, there is evidence for IFN-beta -specific signalling via the alpha/beta receptor (1, 6, 11, 28, 29, 33) and, in human fibrosarcoma cells at least, for a set of genes (including that encoding the double-stranded RNA-activated protein kinase, whose antiviral activity has been well studied [38]) that are preferentially or exclusively induced by IFN-beta (10, 31). On its own, however, this model does not explain our observation, and that of others (13), that IFN-alpha induction is impaired in IFN-beta -/- MEFs. A second mechanism that does not rely on differential signaling by IFN-beta and IFN-alpha is suggested by this observation. Thus, it is possible that only IFNbeta is induced directly by viral infection and that IFN-alpha induction is a consequence of this initial IFN-beta expression. Previous work showing that induction of IFNalpha , but not IFNbeta , requires protein synthesis (14) is consistent with this model, as are data (21, 35, 37, 45, 47) describing a direct pathway for IFNbeta induction by virus involving the transcription factor IRF-3. In a combination of these two mechanisms, viral infection might directly induce only IFN-beta expression, and differential signaling by IFN-alpha and IFN-beta could still be possible, with IFN-beta specifically inducing IFN-alpha expression. The interesting observation that, in mice, IFN-alpha can be induced by IFN-beta but IFN-beta cannot be induced by IFNalpha (3), is probably most compatible with this model. Further experiments, including the injection of specific IFN-alpha /beta subtypes into infected IFN-beta -/- mice, are required to test these possibilities.

Vaccinia virus encodes a number of strategies to block IFN responses, including a soluble receptor for IFN-alpha /beta (5, 42) that needs to be considered when interpreting results from infected mice. The vaccinia virus IFN-alpha /beta receptor expressed from the strain Western Reserve binds to both mouse IFN-alpha and IFN-beta with lower affinity than to the corresponding human IFNs (42). Furthermore, recent data indicate that this receptor does not block the antiviral effects of mouse IFN-beta , suggesting a poor affinity for this species in vivo (V. P. Smith and A. Alcamí, unpublished data). Thus, in the mouse model we have used here, vaccinia virus does not modify the function of IFN-beta .

A very recent study (23) has shown the IFNalpha 4 gene to differ from other IFNalpha genes and to be similar to the IFNbeta gene in its being induced particularly rapidly and without the need for de novo protein synthesis. It was also shown that IFNalpha genes other than IFNalpha 4 require Stat1 for induction. Other recent studies (21, 35, 37, 45, 47) have shown induction of IFNbeta to require viral modification of preexisting transcription factor IRF-3. It was therefore proposed (23) that IFNbeta and IFNalpha 4 are induced as a primary response to viral infection, via a pathway involving IRF-3 phosphorylation, and that secreted IFN-beta and IFN-alpha -4 cause induction of the remaining IFNalpha genes via the type I receptor and the Jak-STAT pathway. Our data are only partly consistent with this model. Clearly some IFN-alpha inducibility remains in the absence of IFN-beta and it is possible that this remaining induction represents the predicted IFN-alpha -4-dependent component. However, the fact that induction of IFN-alpha -4 itself is markedly compromised in the absence of IFN-beta does not support a direct, and therefore presumably IFN-beta -independent, mechanism for IFN-alpha -4 induction. Clearly, further experiments including deletion of the IFNalpha 4 gene are required to resolve these issues.

One of the aims of this study was to place a reporter gene at the IFNbeta locus so that the kinetics and cellular origin of IFN-beta could be studied during an infection in vivo. Recent reports show that both GFP (15, 24) and CD2 (32) can be used successfully as reporters in targeted mice. We showed that the GFP or CD2 reporter genes in the targeting constructs are induced by viral infection in human cells even when randomly inserted into the genome (Fig. 1c and d). RT-PCR analyses showed further that induction of GFP transcripts occurred in MEFs derived from targeted mice (Fig. 2). So far, however, we have been unable to detect GFP fluorescence by flow cytometry in virus-infected MEFs, although we have detected the induction of GFP in Western blots (R. Deonarain, unpublished results). It appears that a different form of GFP is required for the detection of GFP fluorescence in targeted MEFs, although targeted cell types that normally express IFN-beta more abundantly than MEFs may yet allow induction to be followed by fluorescence.


    ACKNOWLEDGMENTS

We thank Neil A. Bryant and Zoe Webster for technical assistance and David Melton for providing HM-1 cells.

This work was funded by an MRC/GlaxoWellcome joint studentship (R.D.) and the Wellcome Trust. A.A. is a Wellcome Trust Senior Research Fellow.


    FOOTNOTES

* Corresponding authors. Mailing address for Andrew C. G. Porter: Gene Targeting Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Rd., London W12 ONN, United Kingdom. Phone: 44 181 383 8276. Fax: 44 181 383 8303. E-mail: andy.porter{at}csc.mrc.ac.uk. Phone for D. R. Gewert: 44 223 575527. Fax: 44 223 575528. E-mail: gewert{at}dialstart.net.


    REFERENCES
Top
Abstract
Text
References

1. Abramovich, C., J. Chebath, and M. Revel. 1994. The human interferon alpha-receptor protein confers differential responses to human interferon-beta versus interferon-alpha subtypes in mouse and hamster cell transfectants. Cytokine 6:414-424[CrossRef][Medline].
2. Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167[CrossRef][Medline].
3. Asano, M., M. Hayashi, E. Yoshida, Y. Kawade, and Y. Iwakura. 1990. Induction of interferon-alpha by interferon-beta, but not of interferon-beta by interferon-alpha, in the mouse. Virology 176:30-38[CrossRef][Medline].
4. Billiau, A., M. Joniau, and P. De Somer. 1973. Mass production of human interferon in diploid cells stimulated by poly-I:C. J. Gen. Virol. 19:1-8[Abstract/Free Full Text].
5. Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:15974-15978[Abstract/Free Full Text].
6. Croze, E., D. Russell Harde, T. C. Wagner, H. Pu, L. M. Pfeffer, and H. D. Perez. 1996. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J. Biol. Chem 271:33165-33168[Abstract/Free Full Text].
7. Darnell, J. E., Jr. 1997. STATs and gene regulation. Science 277:1630-1635[Abstract/Free Full Text].
8. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421[Abstract/Free Full Text].
9. Deonarain, R. K. 1999. Ph.D. thesis. University of London, London, United Kingdom.
10. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623-15628[Abstract/Free Full Text].
11. Domanski, P., O. W. Nadeau, L. C. Platanias, E. Fish, M. Kellum, P. Pitha, and O. R. Colamonici. 1998. Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J. Biol. Chem. 273:3144-3147[Abstract/Free Full Text].
12. Dron, M., M. Lacasa, and M. G. Tovey. 1990. Priming affects the activity of a specific region of the promoter of the human beta interferon gene. Mol. Cell. Biol. 10:854-858[Abstract/Free Full Text].
13. Erlandsson, L., R. Blumenthal, M. L. Eloranta, H. Engel, G. Alm, S. Weiss, and T. Leanderson. 1998. Interferon-beta is required for interferon-alpha production in mouse fibroblasts. Curr. Biol. 8:223-226[CrossRef][Medline].
14. Gobl, A. E., B. Cederblad, K. Sandberg, and G. V. Alm. 1992. Interferon-alpha but not -beta genes require de novo protein synthesis for efficient expression in human monocytes. Scand. J. Immunol. 35:177-185[CrossRef][Medline].
15. Godwin, A. R., H. S. Stadler, K. Nakamura, and M. R. Capecchi. 1998. Detection of targeted GFP-Hox gene fusions during mouse embryogenesis. Proc. Natl. Acad. Sci. USA 95:13042-13047[Abstract/Free Full Text].
16. Hiscott, J., H. Nguyen, and R. Lin. 1995. Molecular mechanisms of interferon beta gene induction. Semin. Virol. 6:161-173.
17. Hogan, B., R. Beddington, F. Constantini, and E. Lacy. 1994. Manipulating the mouse embryo: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
18. Kelley, K. A., and P. M. Pitha. 1985. Characterization of a mouse interferon gene locus. I. Isolation of a cluster of four alpha interferon genes. Nucleic Acids Res. 13:805-823[Abstract/Free Full Text].
19. Kelley, K. A., N. B. Raj, M. Kellum, and P. M. Pitha. 1986. Synthesis of fusion and mature murine alpha interferons in Escherichia coli. Gene 45:317-325[CrossRef][Medline].
20. King, P., and S. Goodbourn. 1994. The beta-interferon promoter responds to priming through multiple independent regulatory elements. J. Biol. Chem. 269:30609-30615[Abstract/Free Full Text].
21. Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996[Abstract/Free Full Text].
22. Magin, T. M., J. McWhir, and D. W. Melton. 1992. A new mouse embryonic stem cell line with good germ line contribution and gene targeting frequency. Nucleic Acids Res. 20:3795-3796[Free Full Text].
23. Marie, I., J. E. Durbin, and D. E. Levy. 1998. Differential viral induction of distinct interferon-a genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660-6669[CrossRef][Medline].
24. Naramura, M., R. J. Hu, and H. Gu. 1998. Mice with a fluorescent marker for interleukin 2 gene activation. Immunity 9:209-216[CrossRef][Medline].
25. Pavlovic, J., A. Schroder, A. Blank, F. Pitossi, and P. Staeheli. 1993. Mx proteins: GTPases involved in the interferon-induced antiviral state. Ciba Found. Symp. 176:233-243[Medline].
26. Pilon, M., M. Gullberg, and E. Lundgren. 1991. Transient expression of the CD2 cell surface antigen as a sortable marker to monitor high frequency transfection of human primary B cells. J. Immunol. 146:1047-1051[Abstract].
27. Pitha, P. M., and W. C. Au. 1995. Induction of interferon alpha genes expression. Semin. Virol. 6:151-159.
28. Platanias, L. C., P. Domanski, O. W. Nadeau, T. Yi, S. Uddin, E. Fish, B. G. Neel, and O. R. Colamonici. 1998. Identification of a domain in the beta subunit of the type I interferon (IFN) receptor that exhibits a negative regulatory effect in the growth inhibitory action of type I IFNs. J. Biol. Chem. 273:5577-5581[Abstract/Free Full Text].
29. Platanias, L. C., S. Uddin, P. Domanski, and O. R. Colamonici. 1996. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. J. Biol. Chem. 271:23630-23633[Abstract/Free Full Text].
30. Prasher, D. C. 1995. Using GFP to see the light. Trends Genet. 11:320-323[CrossRef][Medline].
31. Rani, M. R. S., G. R. Foster, S. Leung, D. Leaman, G. R. Stark, and R. M. Ransohoff. 1996. Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J. Biol. Chem. 271:22878-22884[Abstract/Free Full Text].
32. Riviere, I., M. J. Sunshine, and D. R. Littman. 1998. Regulation of IL-4 expression by activation of individual alleles. Immunity 9:217-228[CrossRef][Medline].
33. Runkel, L., L. Pfeffer, M. Lewerenz, D. Monneron, C. H. Yang, A. Murti, S. Pellegrini, S. Goelz, G. Uze, and K. Mogensen. 1998. Differences in activity between alpha and beta type I interferons explored by mutational analysis. J. Biol. Chem. 273:8003-8008[Abstract/Free Full Text].
34. Samuel, C. E. 1991. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11[CrossRef][Medline].
35. Sato, M., N. Tanaka, N. Hata, E. Oda, and T. Taniguchi. 1998. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett. 425:112-116[CrossRef][Medline].
36. Savage, P., V. Horton, J. Moore, M. Owens, P. Witt, and M. E. Gore. 1996. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br. J. Cancer 74:1482-1486[Medline].
37. Schafer, S. L., R. Lin, P. A. Moore, J. Hiscott, and P. M. Pitha. 1998. Regulation of type I interferon gene expression by interferon regulatory factor-3. J. Biol. Chem. 273:2714-2720[Abstract/Free Full Text].
38. Sen, G. C., and R. M. Ransohoff. 1993. Interferon-induced antiviral actions and their regulation. Adv. Virus Res. 42:57-102[Medline].
39. Smith, G. L., J. A. Symons, and A. Alcami. 1998. Poxviruses: interfering with interferon. Semin. Virol. 8:409-418[CrossRef].
40. Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcami. 1997. Vaccinia virus immune evasion. Immunol. Rev. 159:137-154[CrossRef][Medline].
41. Suzuki, F., N. Ishida, T. Sato, and S. Suzuki. 1975. Effect of the interferon inducer, dextran phosphate, on influenza virus infection in mice. Proc. Soc. Exp. Biol. Med. 149:1069-1075[Abstract].
42. Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560[CrossRef][Medline].
43. van den Broek, M. F., U. Muller, S. Huang, M. Aguet, and R. M. Zinkernagel. 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69:4792-4796[Abstract].
44. van den Broek, M. F., U. Muller, S. Huang, R. M. Zinkernagel, and M. Aguet. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148:5-18[CrossRef][Medline].
45. Wathelet, M. G., C. H. Lin, B. S. Parekh, L. V. Ronco, P. M. Howley, and T. Maniatis. 1998. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell 1:507-518[CrossRef][Medline].
46. Wurst, W., and A. L. Joyner. 1993. Production of targeted embryonic stem cell clones, p. 33-61. In A. L. Joyner (ed.), Gene targeting: a practical approach. IRL Press, Oxford, United Kingdom.
47. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita. 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17:1087-1095[CrossRef][Medline].


Journal of Virology, April 2000, p. 3404-3409, Vol. 74, No. 7
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deonarain, R.
Right arrow Articles by Porter, A. C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deonarain, R.
Right arrow Articles by Porter, A. C. G.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS